NeoGenomics Q2 revenue beats estimates, raises outlook

Overview

• Oncology diagnostics firm's Q2 revenue rose 11% yr/yr, beating analyst expectations

• Adjusted EPS for Q2 beat consensus

• Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook

• NeoGenomics raises full-year 2026 revenue guidance to $802 mln-$806 mln

• Company increases full-year 2026 adjusted EBITDA guidance to $56 mln-$58 mln

• NeoGenomics expects full-year 2026 GAAP net loss of $42 mln-$34 mln

Result Drivers

• NGS GROWTH - Co said 26% yr/yr growth in next-generation sequencing revenue contributed to overall revenue increase

• HIGHER PRICING - Average revenue per clinical test rose 12% to $515, supporting revenue growth

• COST DISCIPLINE - Operating expenses fell 19%, mainly due to absence of prior-year impairment charges

Company press release: ID:nBw6VWBT9a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities services peer group is "buy"

• Wall Street's median 12-month price target for Neogenomics Inc is $16.00, about 21.8% above its July 27 closing price of $13.14

• The stock recently traded at 46 times the next 12-month earnings vs. a P/E of 38 three months ago

Reuters Recommended Reads

• July 27 - Champions Oncology Q4 revenue rises; margin improves driven by cost discipline

• July 28 - IQVIA raises annual profit forecast on clinical research demand

• July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)